2024
Epidemiology and risk factors for hyperkalaemia in heart failure
Grobbee D, Filippatos G, Desai N, Coats A, Pinto F, Rosano G, Cleland J, Kammerer J, de Arellano A. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure 2024, 11: 1821-1840. PMID: 38439165, PMCID: PMC11287317, DOI: 10.1002/ehf2.14661.Peer-Reviewed Original ResearchHeart failureObservational studyRisk factorsRenin-angiotensin-aldosterone system inhibitorsSevere renal impairmentElevated serum potassiumImpaired renal functionRisk of hyperkalaemiaIncreased risk of mortalityAdverse cardiovascular eventsClinical epidemiological dataFollow-up lengthChronic kidney diseaseRisk of mortalityIdentified risk factorsMild hyperkalaemiaPotassium bindersRenal impairmentConcomitant medicationsHF therapyDiagnosed HFRenal functionSerum potassiumClinical careClinical outcomes
2022
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Jun T, Hahn N, Sonpavde G, Albany C, MacVicar G, Hauke R, Fleming M, Gourdin T, Jana B, Oh W, Taik P, Wang H, Varadarajan A, Uzilov A, Galsky M. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. The Oncologist 2022, 27: 432-e452. PMID: 35438782, PMCID: PMC9177111, DOI: 10.1093/oncolo/oyab075.Peer-Reviewed Original ResearchConceptsProgression-free survivalImpaired renal functionAdvanced urothelial carcinomaCisplatin-ineligible patientsPhase II trialUrothelial carcinomaCohort 2Cohort 1Renal functionII trialClinical benefitAdverse eventsOpen-label phase II trialDiscontinuation due to adverse eventsMedian progression-free survivalActivity of everolimusPlatinum-based chemotherapyAssociated with treatment benefitFirst-line therapyPoor performance statusFunctional statusAdvanced UCMetastatic UCCisplatin-ineligibleSlow accrual
2020
Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study
Hawkes C, Roy S, Dekelbab B, Frazier B, Grover M, Haidet J, Listman J, Madsen S, Roan M, Rodd C, Sopher A, Tebben P, Levine M. Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study. The Journal Of Clinical Endocrinology & Metabolism 2020, 106: e485-e495. PMID: 33124662, PMCID: PMC7823241, DOI: 10.1210/clinem/dgaa759.Peer-Reviewed Original ResearchConceptsAcute hypercalcemiaKetogenic dietLevels of 1,25-dihydroxyvitamin DLow levels of parathyroid hormoneLevels of parathyroid hormoneLow alkaline phosphatase levelMulticenter case seriesImpaired renal functionCohort of patientsResolution of hypercalcemiaReduced osteoblast activityResponse to treatmentAlkaline phosphatase levelsImpaired bone formationRenal impairmentClinical presentationRenal functionParathyroid hormoneCase seriesMulticenter studyClinical characteristicsBone healthHypercalcemiaSkeletal demineralizationFollow-up
2017
Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy
Kronbichler A, Oh J, Meijers B, Mayer G, Shin J. Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy. BioMed Research International 2017, 2017: 1936372. PMID: 28904948, PMCID: PMC5585565, DOI: 10.1155/2017/1936372.Peer-Reviewed Original ResearchConceptsPrimary membranous nephropathyMembranous nephropathyThrombospondin type-1 domain-containing 7AM-type phospholipase A2 receptorFrequency of spontaneous remissionReduction of proteinuriaImpaired renal functionPhospholipase A2 receptorRecurrence of diseaseDecline of kidney functionChildhood MNPLA2R1 geneImmunological remissionPLA2R antibodyHigher proteinuriaPrimary MNRenal functionRenal transplantationSpontaneous remissionTreatment resistanceA2 receptorsEpitope spreadingNephrotic syndromeTreatment responseCationic bovine serum albumin
2013
Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis
Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis. American Journal Of Dermatopathology 2013, 35: 351-356. PMID: 23051628, DOI: 10.1097/dad.0b013e31826c5508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesCaveolin 1Chi-Square DistributionCodonContrast MediaFemaleFibrosisGadoliniumGene FrequencyGenetic Predisposition to DiseaseHumansIntronsMaleMiddle AgedMultivariate AnalysisNephrogenic Fibrosing DermopathyPhenotypePolymorphism, Single NucleotideRisk FactorsTransforming Growth Factor beta1ConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsSingle nucleotide polymorphismsSystemic fibrosisDevelopment of NSFImpaired renal functionChronic kidney diseaseCohort of patientsSubset of patientsProgression of fibrosisRenal impairmentRenal functionKidney diseaseControl subjectsNSF casesHistological evidenceGenetic predispositionPatientsIntronic single nucleotide polymorphismOrgan systemsFibrosisGenotype frequenciesTGFB1Significant differencesDisease
2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Leal T, Remick S, Takimoto C, Ramanathan R, Davies A, Egorin M, Hamilton A, LoRusso P, Shibata S, Lenz H, Mier J, Sarantopoulos J, Mani S, Wright J, Ivy S, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy And Pharmacology 2011, 68: 1439-1447. PMID: 21479634, PMCID: PMC3481841, DOI: 10.1007/s00280-011-1637-5.Peer-Reviewed Original ResearchConceptsSevere renal dysfunctionNormal renal functionRenal dysfunctionAdult cancer patientsRenal functionDialysis patientsDose escalationCancer patientsPatient populationNational Cancer Institute Organ Dysfunction Working Group StudyDose of bortezomibImpaired renal functionGeneral patient populationIntravenous bortezomibRenal impairmentCreatinine clearanceModerate dysfunctionMild dysfunctionSevere dysfunctionDose reductionPharmacologic dataPatientsDay 1DysfunctionBortezomib
2009
Impact of Baseline Renal Function on Outcomes of Renal Artery Stenting in Hypertensive Patients
Singer GM, Remetz MS, Curtis JP, Setaro JF. Impact of Baseline Renal Function on Outcomes of Renal Artery Stenting in Hypertensive Patients. Journal Of Clinical Hypertension 2009, 11: 615-620. PMID: 19878369, PMCID: PMC8673102, DOI: 10.1111/j.1751-7176.2009.00167.x.Peer-Reviewed Original ResearchConceptsRenal artery stentingSystolic blood pressureBlood pressureRenal functionArtery stentingObstructive renal artery diseaseResistant hypertension patientsBaseline renal functionImpaired renal functionGlomerular filtration rateRenal artery diseaseHypertensive patientsRenal dysfunctionArtery diseaseConsecutive patientsHypertension patientsRenal arteryFiltration ratePatientsEGFRGreat benefitMonthsStentingHgArtery
2005
The significance of elevated troponin T in patients with nondialysis‐dependent renal insufficiency: A validation with coronary angiography
Heitner JF, Curtis JP, Haq SA, Corey GR, Newby LK, Jollis JG. The significance of elevated troponin T in patients with nondialysis‐dependent renal insufficiency: A validation with coronary angiography. Clinical Cardiology 2005, 28: 333-336. PMID: 16075826, PMCID: PMC6653870, DOI: 10.1002/clc.4960280706.Peer-Reviewed Original ResearchConceptsPoor renal functionCoronary artery diseaseLength of stayNondialysis-dependent renal insufficiencyElevated troponin TNormal renal functionRenal functionElevated cTnTCoronary angiographyCAD stenosisContrast nephropathyPositive cTnTRenal insufficiencyPrevalence of CADTroponin TSignificant coronary artery diseaseSignificant coronary artery stenosisImpaired renal functionAcute coronary syndromeFuture cardiac eventsInitiation of hemodialysisGlomerular filtration rateCoronary artery stenosisElevated cTnT.Hospital mortality
2001
Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure
Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, Stone GW, Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheterization And Cardiovascular Interventions 2001, 55: 66-72. PMID: 11793497, DOI: 10.1002/ccd.10103.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic renal failurePercutaneous coronary interventionClinical outcomesLate mortalityRenal dysfunctionCoronary interventionRenal failureRenal functionRenal diseaseHigher left ventricular ejection fractionNon-Q-wave myocardial infarctionLeft ventricular ejection fractionAngiographic success rateImpaired renal functionNormal renal functionVentricular ejection fractionHospital mortalityCreatinine clearanceConsecutive patientsDiabetes mellitusEjection fractionIndependent correlatesMyocardial infarctionLarge cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply